Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. - Wikidata - wikimedia - TriplyDB

Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia.

Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia.

http://www.wikidata.org/entity/Q34735496

about

Biologic complexity in sickle cell disease: implications for developing targeted therapeutics Drugs for preventing red blood cell dehydration in people with sickle cell disease Drugs for preventing red blood cell dehydration in people with sickle cell disease Drugs for preventing red blood cell dehydration in people with sickle cell disease The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans Autosomal dominant polycystic kidney disease: the last 3 years Experimental therapies and ongoing clinical trials to slow down progression of ADPKD Ion Channels in Brain Metastasis Molecular mechanisms underlying synergistic adhesion of sickle red blood cells by hypoxia and low nitric oxide bioavailability.Hypoxia activates a Ca2+-permeable cation conductance sensitive to carbon monoxide and to GsMTx-4 in human and mouse sickle erythrocytes.Ca(2+)-activated K(+) channel-3.1 blocker TRAM-34 attenuates airway remodeling and eosinophilia in a murine asthma model.Treating sickle cell disease by targeting HbS polymerization Placenta growth factor in sickle cell disease: association with hemolysis and inflammation.Treatment strategies and clinical trial design in ADPKD Ion channels regulating mast cell biology.Increased constitutive αSMA and Smad2/3 expression in idiopathic pulmonary fibrosis myofibroblasts is KCa3.1-dependent.Cyclic AMP-mediated cyst expansion Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions Management of sickle cell disease: a review for physician education in Nigeria (sub-saharan Africa).The Ca²⁺-activated K⁺ channel KCa3.1 as a potential new target for the prevention of allograft vasculopathy.The K+ channel KCa3.1 as a novel target for idiopathic pulmonary fibrosis Pharmacotherapy in sickle cell disease--state of the art and future prospects Human lung myofibroblast TGFβ1-dependent Smad2/3 signalling is Ca(2+)-dependent and regulated by KCa3.1 K(+) channels Anti-haemolytic effect of senicapoc and decrease in NT-proBNP in adults with sickle cell anaemia.Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease.Trpc2 depletion protects red blood cells from oxidative stress-induced hemolysis.Piezo1 links mechanical forces to red blood cell volume The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke.Therapeutic potential of KCa3.1 blockers: recent advances and promising trends.Microglial KCa3.1 Channels as a Potential Therapeutic Target for Alzheimer's Disease Genetic deficit of KCa 3.1 channels protects against pulmonary circulatory collapse induced by TRPV4 channel activation.Trafficking of intermediate (KCa3.1) and small (KCa2.x) conductance, Ca(2+)-activated K(+) channels: a novel target for medicinal chemistry efforts?'Gardos Channelopathy': a variant of hereditary Stomatocytosis with complex molecular regulation The Clinically Tested Gardos Channel Inhibitor Senicapoc Exhibits Antimalarial Activity.Cation Homeostasis in Red Cells From Patients With Sickle Cell Disease Heterologous for HbS and HbC (HbSC Genotype).Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease.Vascular KCa-channels as therapeutic targets in hypertension and restenosis disease.The potassium channel KCa3.1 as new therapeutic target for the prevention of obliterative airway disease.Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels.Ion channel regulation of intracellular calcium and airway smooth muscle function.

P2860

Q21284789-76B4E3E2-E945-4FDC-872D-B85CD772012C Q24186046-1AF3A81B-5CC2-40E9-B342-F54321E85230 Q24202032-FFCFFD57-D537-40E0-9461-40F1F0CB1246 Q24240777-52FF4086-B05B-46FA-BA0B-DC492D61DF8A Q24648765-A9C27A15-F7A9-4530-BBA1-786C41E6854A Q24656249-8B15DA3F-ADBA-4E81-926E-219016D5DCF8 Q27001230-59D8D134-D008-4F40-A99F-C1E261AF4505 Q28078185-8F5C54EC-4355-4B50-9923-1B21D2877ACF Q30574476-4038BB75-5E35-444A-B1F3-984939145402 Q33525570-A1BE218E-1946-4A9E-AE72-2E35DAB799EF Q33670161-75340A21-4A2D-4AC3-87FF-1D4D46C17288 Q33707352-5E6EC0EE-A506-4280-8C82-8C31BEB07C68 Q33722654-F3EB1CA3-90D2-497B-B1DA-87B8FD1D9050 Q34024396-623086B9-D243-48EA-88F9-0474558E28D9 Q34340292-9DEDA1A3-EE52-43E5-8473-F539FDC2D616 Q34677065-0BD9A238-14E1-46EB-94DA-3E0660E87520 Q34850793-252784F6-CE67-40C8-B1B2-F3A03BC3DE05 Q34992760-13F9A7BE-B5DF-40CE-8866-3144D2D9F8D9 Q35034032-485F91DD-CF05-42AE-8BF6-F0E125DF56B1 Q35060404-143B3133-C0D3-4837-A4E5-A2302FFB921A Q35083097-89A68433-AF35-4BFC-B987-5F7B1CFB5F49 Q35220342-8118DFE3-F3CB-4F74-8A5D-1F62CA289996 Q35232951-DE38502C-9731-4C77-9798-04ADE7329D3A Q35549141-F3CEC06C-D202-4B49-AF95-2D583F254A5D Q35576474-BFE34F86-E018-4802-9FE4-71C03765EA73 Q35613275-BFA84F29-E88F-4458-83E7-401E4278ABB9 Q35639548-8C03F8AD-C236-4927-8FC0-5956D1757D53 Q35880549-15A49325-58AB-4C44-9377-206C300E3779 Q35944615-08F00550-EC13-4C3B-BCFA-7331A19CDB67 Q35999547-031BE172-DD2D-4CFC-BE5A-B1590735190B Q36036232-BE0EF8EC-0853-4E66-9796-7FCA371EE6E7 Q36269118-4B0D9B7A-1A0F-4F60-9920-2757BFF13D13 Q36369767-A975E613-0D68-4392-AD65-D39799340352 Q36438976-29D81B01-7AD4-49F0-B8E9-D95FEA9EA48E Q36540959-857CB910-B3A6-44DD-B11A-603391D703BF Q36596855-8FAF00D3-8223-4780-B426-B02FFEBA1AA0 Q36815916-0521F5FD-F90D-4C3B-9449-C61C9C45D8AE Q37184567-E927BA0B-5406-4BD5-AF2F-F27F9D2D7D3E Q37305118-703257B1-65F7-4602-AFC7-C75E179977F9 Q37325179-DE3F30C0-94B3-4F74-9586-917388D91189

P2860

Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia.

http://www.wikidata.org/entity/Q34735496

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Efficacy and safety of the Gar ...... ients with sickle cell anemia.

@ast

Efficacy and safety of the Gar ...... ients with sickle cell anemia.

@en

Efficacy and safety of the Gar ...... ients with sickle cell anemia.

@nl

type

label

Efficacy and safety of the Gar ...... ients with sickle cell anemia.

@ast

Efficacy and safety of the Gar ...... ients with sickle cell anemia.

@en

Efficacy and safety of the Gar ...... ients with sickle cell anemia.

@nl

prefLabel

Efficacy and safety of the Gar ...... ients with sickle cell anemia.

@ast

Efficacy and safety of the Gar ...... ients with sickle cell anemia.

@en

Efficacy and safety of the Gar ...... ients with sickle cell anemia.

@nl

P1433

Q34735496-741E69CC-E9B4-4A1A-86CC-D97CD037E178

P1476

Q34735496-B14D8D47-2708-41E2-861D-4EABCC646AF2

P2093

Q34735496-37E5D979-2376-475E-9A99-21119517B869

Q34735496-3845DF46-939C-4C71-8068-6012561DFB01

Q34735496-3B881823-A6BB-456C-95C5-BACD2B20B78E

Q34735496-78ADB578-44E7-441D-986E-40C6F920B17B

Q34735496-8AA08567-0B1C-4AC5-87A2-CC53641B9993

Q34735496-9F7E2883-1801-47CA-83AF-490029355483

Q34735496-AD3617FB-5633-494B-8F63-B5AE98F6D1F6

Q34735496-C7846D8F-7779-4F8F-AD95-457433E9A5CE

Q34735496-D4C77398-7342-4F61-932B-938D8A45D467

Q34735496-E645D615-7F16-4C67-A34C-5AAF681405D2

P304

Q34735496-44DC1F22-4FC6-472A-8C13-44A110906B48

P31

Q34735496-1FB70D71-205E-4E80-B158-6B4764454ECA

P356

Q34735496-7C993B5A-DC03-4024-9968-9822FD004D2D

P407

Q34735496-DCB4337F-A3E7-4A36-B214-6916FD520C54

P433

Q34735496-DC567CBB-9507-4777-A07B-79A2FBD99F14

P478

Q34735496-F6F52A8C-F4EF-4809-AF8D-2ECD3F7AB74B

P577

Q34735496-E045EA7D-963E-4514-8CB0-2280BAD8816D

P5875

Q34735496-38923671-0F7E-44D5-83BD-F72FC294348B

P698

Q34735496-AE8C258E-97EB-4A7C-A562-AA8A5A38F08D

P921

Q34735496-79A72D9F-062E-4117-8015-2FE5A9FB414F

Q34735496-E6609672-99CF-4B55-8A2B-6153BF2B4E52

P356

BLOOD-2007-08-110098

P1433

P1476

Efficacy and safety of the Gar ...... ients with sickle cell anemia.

@en

P2093

Abdullah Kutlar

http://www.w3.org/2001/XMLSchema#string

Elliot Vichinsky

http://www.w3.org/2001/XMLSchema#string

Eugene P Orringer

http://www.w3.org/2001/XMLSchema#string

Greg C Rigdon

http://www.w3.org/2001/XMLSchema#string

ICA-17043-05 Investigators

http://www.w3.org/2001/XMLSchema#string

Jonathan W Stocker

http://www.w3.org/2001/XMLSchema#string

Kenneth I Ataga

http://www.w3.org/2001/XMLSchema#string

Laura M De Castro

http://www.w3.org/2001/XMLSchema#string

Oswaldo Castro

http://www.w3.org/2001/XMLSchema#string

Paul Swerdlow

http://www.w3.org/2001/XMLSchema#string

P304

3991-3997

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2007-08-110098

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P577

2008-01-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5658084

http://www.w3.org/2001/XMLSchema#string

P698

18192510

http://www.w3.org/2001/XMLSchema#string

P921

sickle-cell disease